CLDN3 and ovarian cancer: ZDHHC12 mediates palmitoylation of claudin 3 (CLDN3) at Cys103, Cys106, Cys181, Cys182, and Cys184 to enhance ovarian cancer progression and, reversely, defective CLDN3 palmitoylation inhibits membrane localization and protein stability of CLDN3, with a negative impact on ovarian cancer cell growth [90].